On this page
Quick Reference
Overview and Recommendations
Background
- •Recognize myasthenia gravis as a chronic of the characterized by a bimodal age distribution. Early-onset disease predominantly affects women in their 20s and 30s, while late-onset disease (LOMG) is increasingly diagnosed in patients over age 65, often presenting with more severe initial symptoms and higher comorbidity burdens.
- •Understand the primary pathophysiology involving pathogenic autoantibodies that interfere with synaptic transmission. Approximately 80% of generalized MG patients possess antibodies against the acetylcholine receptor (AChR-Ab), while 5-8% have antibodies against muscle-specific kinase (MuSK-Ab), which often correlates with a more severe bulbar and respiratory phenotype.
- •Identify the critical role of the thymus gland in disease pathogenesis. Thymic hyperplasia is common in early-onset AChR-positive cases, while —a primary thymic epithelial tumor—is present in approximately 10-15% of all MG patients and necessitates oncological evaluation.
- •Screen for common triggers that can induce new-onset disease or precipitate exacerbations. These include viral infections (notably ), physiological stress, surgery, and specific medications such as , immune checkpoint inhibitors (ICIs), and certain antibiotics.
- •Note the clinical variants, including (OMG), where symptoms are restricted to the extraocular muscles. Approximately 40% of patients with OMG will progress to generalized myasthenia gravis (gMG) within two years of symptom onset.
Evaluation
- •Suspect myasthenia gravis in any patient presenting with fluctuating ptosis, diplopia, slurred speech, or proximal limb weakness that worsens with use. Ask specifically about diurnal variation—symptoms that are better after a night's sleep or a nap but progress throughout the afternoon.
- •Perform a fatigability examination by asking the patient to maintain an upward gaze for 60 seconds to elicit ptosis or to count aloud from 1 to 100 to detect progressive dysarthria or a nasal quality to the voice.
- •Utilize the ice pack test at the bedside for patients with ptosis; application of an ice pack to the affected eyelid for 2 minutes that results in ≥2 mm of improvement is highly suggestive of MG due to the temperature sensitivity of acetylcholinesterase.
- •Order serum autoantibody testing as the initial diagnostic step. Obtain AChR-binding, blocking, and modulating antibodies; if negative and the clinical suspicion for generalized MG is high, reflex to MuSK-Ab and LRP4-Ab testing.
- •Perform repetitive nerve stimulation (RNS) in a weak muscle, looking for a >10% decremental response in the compound muscle action potential (CMAP) at low-frequency (2-3 Hz) stimulation.
- •Request single-fiber electromyography (SFEMG) if serology is negative but clinical suspicion remains high. This is the most sensitive diagnostic test for MG, showing increased 'jitter' or impulse blocking, though it is technically demanding and less specific than antibody testing.
- •Obtain a CT or MRI of the chest in all newly diagnosed patients to rule out , regardless of the severity of symptoms or antibody status.
- •Evaluate respiratory mechanics immediately if the patient reports dyspnea or exhibits bulbar weakness. Measure the Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP); an FVC < 15 mL/kg or MIP < -30 cmH2O indicates an impending crisis.
- •Rule out mimics such as (characterized by autonomic dysfunction and strength that improves with exercise) and (characterized by loss of deep tendon reflexes and ascending paralysis).
- •Assess for the 'curtain sign' during the ocular exam: manually lifting the more ptotic eyelid may cause the contralateral eyelid to droop further, demonstrating the shared neural drive (Hering's Law) and compensatory effort.
Management
- •Administer Pyridostigmine 60 mg orally every 4 to 6 hours as the first-line symptomatic treatment for most patients. Adjust the dose based on clinical response and tolerance of cholinergic side effects like abdominal cramping or diarrhea.
- •Initiate Prednisone 0.5 to 1.0 mg/kg/day for patients who remain symptomatic on pyridostigmine. Start at a low dose (e.g., 10-20 mg/day) and titrate upward slowly to avoid the transient 'steroid flare'—a paradoxical worsening of weakness that can occur in the first two weeks of high-dose therapy.
- •Introduce steroid-sparing agents such as Azathioprine 2-3 mg/kg/day or Mycophenolate mofetil 1000 mg twice daily for long-term maintenance. Counsel patients that these agents may take 6 to 12 months to reach full clinical efficacy.
- •Refer for in patients aged 18-65 with AChR-positive generalized MG. Surgical removal of the thymus increases the probability of remission and reduces the long-term requirement for corticosteroids.
- •Manage an impending myasthenic crisis (IMC) with rapid-acting immunomodulation. Administer Efgartigimod 10 mg/kg IV weekly for 4 weeks; this FcRn antagonist rapidly reduces IgG levels and has shown superior early improvement compared to traditional therapies.
- •Utilize Intravenous Immunoglobulin (IVIg) 2 g/kg divided over 2 to 5 days or Plasmapheresis (PLEX) for 5 to 7 exchanges as alternative rescue therapies for acute exacerbations or as a preoperative bridge.
- •Escalate to C5 inhibitors such as Eculizumab or Ravulizumab for patients with refractory AChR-positive generalized MG who fail conventional immunosuppression.
- •Avoid medications known to exacerbate neuromuscular blockade. Strictly contraindicated or high-risk drugs include Magnesium sulfate, aminoglycosides (e.g., Gentamicin), fluoroquinolones (e.g., Ciprofloxacin), and beta-blockers.
- •Monitor respiratory status closely during exacerbations. Do not rely solely on oxygen saturation; intubate electively if the patient develops severe dysphagia (bulbar failure) or if the FVC drops below 15 mL/kg to prevent aspiration and sudden respiratory arrest.
- •Maintain a 'Nothing by Mouth' (NPO) status for any patient with a Quantitative Myasthenia Gravis (QMG) bulbar subscore ≥2 to prevent , which is a leading cause of mortality in myasthenic crisis.
- •Transition pregnant patients to the safest possible regimen. Use Pyridostigmine and Prednisone as first-line; avoid Mycophenolate and Methotrexate due to teratogenicity. Be prepared for transient neonatal myasthenia in 10-20% of newborns due to maternal antibody transfer.
Board Review — High Yield
- •Cogan's lid twitch — Brief overshoot of the upper eyelid when shifting gaze from downward to primary position.
- •MuSK-positive MG — Often presents with severe bulbar/respiratory weakness and may be worsened by Pyridostigmine.
- •Thymoma — Found in 10-15% of MG; requires surgical resection regardless of MG severity.
- •Ice pack test — Positive if ptosis improves by ≥2mm after 2 minutes of cooling (inhibits acetylcholinesterase).
- •Myasthenic Crisis — Respiratory failure requiring mechanical ventilation; usually triggered by infection or medication changes.
- •Decrement on RNS — A >10% drop in CMAP amplitude between the 1st and 4th/5th stimuli at 2-3 Hz.
- •Hering's Law of Equal Innervation — Explains the 'curtain sign' where lifting one eyelid worsens ptosis in the other.
- •Transient Neonatal MG — Occurs in 10-20% of infants born to MG mothers; caused by passive transfer of IgG antibodies.
Deep Dive — Evidence Details
Epidemiology and Risk Factors
- ▸Myasthenia gravis incidence is rising significantly in the elderly population (>65 years), often presenting diagnostic challenges due to comorbidities [2].
- ▸Obesity (BMI ≥ 30) is a confirmed risk factor for new-onset MG, likely due to systemic inflammation [13].
- ▸Infections, including the common cold and COVID-19, are the primary triggers for disease exacerbation and initial presentation [9, 17].
Myasthenia gravis (MG) is a rare chronic of the characterized by a bimodal age distribution and complex interactions between genetic predisposition and environmental triggers. While historically considered a disease of the young, recent temporal trends indicate a significant rise in the incidence and prevalence of the condition among the elderly [2].
Incidence and Prevalence
The global of MG is shifting, with an increasing burden in the very old (defined as age >65 years) [2]. In women, the onset age distribution frequently peaks within the reproductive age range, which complicates clinical during pregnancy and the postpartum period [1]. In contrast, childhood-onset myasthenia gravis (CMG) remains rare, though its incidence is reportedly increasing annually in certain regions, such as China, where it accounts for 10.3% to 12.6% of new cases [17]D. CMG typically exhibits a single peak at ages 1–3 years [17]D.
Serological status also varies by clinical phenotype. In patients with (OMG), approximately 45.9% are positive for acetylcholine receptor antibodies (AChR-Ab+), while the remainder are seronegative [8]. The presence of these antibodies in OMG is a known risk factor for progression to generalized myasthenia gravis (gMG) [8].
Demographic Distribution
MG exhibits a distinct sex-based predilection that varies by age of onset:
- Early-Onset MG: Predominantly affects women, particularly those in their 20s and 30s [1].
- Late-Onset MG (LOMG): Defined as onset after age 50 or 65, this group shows an increasing incidence, likely due to unknown environmental factors and improved diagnostic recognition in the elderly [2][10].
- Childhood-Onset MG: In large cohorts, the male-to-female ratio is approximately 1:1.4, with a median onset age of 5 years [17]D.
Risk Factors and Triggers
Metabolic and Lifestyle Factors
Obesity has emerged as a significant risk factor for the development of MG. A nationwide cohort study found that individuals with a BMI ≥ 30.0 (Obese Class II) have a significantly higher risk of newly diagnosed MG (HR 1.33) compared to those with a normal BMI [13]. This association is thought to be mediated by the pro-inflammatory environment induced by excess adipose tissue [13].
Pharmacological Triggers
Several medication classes are associated with the induction or exacerbation of MG:
- : Multinational real-world data suggest a potential risk of new-onset MG following the initiation of statin therapy [15]C.
- Immune Checkpoint Inhibitors (ICIs): These anti-tumor agents can induce neurotoxicity as an immune-related adverse event (irAE). Patients with preexisting MG or are at particularly high risk for severe flares when treated with ICIs [18]D[21]D.
Infectious Triggers
Infections are the most common triggers for both the initial onset and subsequent exacerbations of MG. In childhood-onset cases, the common cold is the most prevalent trigger [17]D. More recently, and Long COVID have been identified as independent predictors of MG exacerbation [3][9]. Long COVID, in particular, serves as a risk factor for increased disease severity and mortality in MG patients [9].
Comorbidities and Associated Risks
Patients with MG have a higher prevalence of several comorbidities compared to the general population. Circulatory diseases, particularly (13–24%), are frequent before diagnosis [24]D. Post-diagnosis, patients often develop anemia and osteoporosis, likely secondary to long-term immunosuppressive therapy [24]D.
There is also a documented increase in the prevalence of extrathymic neoplasms in MG patients (HR 1.34) [11]. While thymectomy is a standard treatment for MG, its long-term impact on the risk of developing other cancers or autoimmune diseases remains a subject of clinical debate [23]D. Furthermore, Mendelian randomization studies suggest that MG may have a causal influence on the risk of neurodegenerative disorders, including Alzheimer disease (AD), (PD), and amyotrophic lateral sclerosis (ALS) [7].
Risk Factor Summary Table
| Risk Factor | Association (OR/RR/HR) | Evidence Level |
|---|---|---|
| Obesity (BMI ≥ 30.0) | HR 1.33 (95% CI 1.01–1.75) | 2b [13] |
| Onset Age ≥ 50 years | HR 1.68 (Relapse risk) | 5 [25]D |
| Extrathymic Neoplasms | HR 1.34 | 3b [11] |
| Long COVID | Independent Predictor of Exacerbation | 2b [9] |
| Family History (CMG) | 1.7% of cases | 5 [17]D |
| Statin Initiation | Potential New-Onset Risk | 4 [15]C |
| Comorbidity | Prevalence/Association | Evidence Level |
|---|---|---|
| Hypertension | 13–24% | 5 [24]D |
| Sleep Disorders | High (contributes to fatigue) | 2a [4] |
| Urinary Dysfunction | Increased UI and OAB symptoms | 3b [12] |
| Psychiatric Disorders | Frequent co-occurrence | 5 [20]D |
| Migraine | Higher prevalence vs. controls | 5 [22]D |
Clinical Features and Variants
- ▸MG ranges from ocular-only disease to generalized weakness with bulbar, limb, axial, or respiratory involvement; gMG trials commonly include MGFA classes II–IV. [138]
- ▸SNMG is defined by compatible clinical and electrophysiologic evidence without detectable antibodies to recognized MG targets; a systematic review included 712 patients, 67% female, with mean onset at 42 years. [141]
- ▸AChR-Ab-positive gMG is the principal population studied in complement-inhibition trials, whereas FcRn studies may include AChR, MuSK, and LRP4 seropositivity. [138] [100]
- ▸Juvenile MG requires age-specific interpretation; a Canadian cohort included 36 patients younger than 18 years, including 16 with generalized disease. [158]
- ▸Patient-reported function, fatigue, quality of life, exacerbations, rescue-treatment use, and healthcare utilization are important expressions of disease burden beyond examination findings. [100] [137] [116]
Clinical spectrum
Myasthenia gravis (MG) is clinically heterogeneous, ranging from weakness restricted to ocular muscles to generalized disease involving bulbar, limb, axial, and respiratory muscles. The contemporary treatment literature largely defines generalized MG (gMG) as clinically significant disease beyond the ocular muscles and commonly stratifies severity using the Myasthenia Gravis Foundation of America (MGFA) classes; the PREVAIL trial enrolled adults with acetylcholine-receptor-antibody-positive (AChR-Ab+) gMG in MGFA classes II–IV. [138] Generalized disease is associated with fluctuating weakness and substantial effects on activities of daily living, fatigue, quality of life, emergency-care use, and hospitalization. [100] [116] Exacerbations may require rescue therapy, particularly in patients with moderate-to-severe uncontrolled gMG. [137]
Ocular myasthenia gravis
Ocular MG (OMG) is characterized by weakness predominantly affecting extraocular muscles, producing fluctuating ptosis and diplopia; refractory OMG remains a clinically challenging subgroup with limited evidence for biologic therapy. [157]C In a systematic review of seronegative MG (SNMG), isolated ocular symptoms were specifically identified as a major clinical presentation, although the supplied abstract does not quantify the proportion. [141] A retrospective real-world study evaluated telitacicept as add-on therapy in refractory OMG using MG-ADL, QMG, and MGII outcomes, together with immunoglobulin, complement, and CD19+ B-cell measurements; these data support investigation of biologically distinct, treatment-refractory ocular disease but do not establish telitacicept as standard therapy. [157]C
Generalized and antibody-associated variants
Seropositive gMG includes patients with antibodies against AChR, muscle-specific kinase (MuSK), or low-density lipoprotein receptor-related protein 4 (LRP4). The VIVACITY-MG3 study enrolled seropositive adults with any of these three antibody specificities, whereas several comparative studies specifically analyzed AChR-Ab-positive gMG. [100] [142] [143] AChR-Ab-positive gMG is particularly relevant to complement-mediated treatment: complement activation is described as a key pathogenic mechanism in this subgroup, and PREVAIL evaluated the C5 inhibitor gefurulimab exclusively in adults with AChR-Ab+ gMG. [138]
The therapeutic evidence base is therefore not interchangeable across antibody subtypes. The 2026 Bayesian network meta-analysis compared treatments in adults with generalized MG, while separate analyses addressed AChR-Ab-positive populations or seropositive populations receiving FcRn-directed therapy. [99] [142] [100] Indirect comparisons have evaluated zilucoplan against IVIg, eculizumab, and ravulizumab, and rozanolixizumab against efgartigimod or IVIg; because these were matching-adjusted indirect comparisons rather than head-to-head trials, their findings should not be interpreted as definitive evidence of superiority. [155] [156]
Seronegative myasthenia gravis
SNMG refers to patients with clinical and electrophysiologic evidence of a postsynaptic neuromuscular-junction disorder despite the absence of detectable autoantibodies against currently recognized MG targets. [141] A systematic review identified 31 studies involving 712 patients; the cohort was predominantly female (473/712; 67%) and had a mean age at onset of 42 years. [141] Diagnostic support in the reviewed literature included compatible clinical features, electrophysiology, pharmacologic testing, and response to treatment. [141] The review emphasizes that SNMG is a clinically defined and diagnostically challenging category rather than proof that autoimmune disease is absent. [141]
Treatment response may also vary within seronegative or apparently refractory disease. In a prospective cohort, 18 patients with poor early response after one efgartigimod cycle were subsequently evaluated for eculizumab, illustrating an investigated sequential-treatment strategy; this evidence is observational and does not establish a general treatment algorithm. [111]C Conversely, the available treatment trials and network analyses primarily provide evidence for selected generalized, often seropositive populations and should not automatically be extrapolated to all SNMG phenotypes. [99] [142]
Juvenile myasthenia gravis
Juvenile MG (JMG) represents disease diagnosed before adulthood and requires age-specific interpretation of phenotype, treatment tolerance, development, and remission. A Canadian single-center retrospective review included 36 patients younger than 18 years diagnosed between 2015 and 2025; diagnosis was confirmed by antibody positivity or electrophysiology, and outcomes were categorized using MGFA postintervention status. [158]C The cohort included both generalized and non-generalized disease, with 16 patients reported as having generalized MG in the supplied abstract. [158]C Because the study was retrospective and single-center, its remission estimates and predictors should be regarded as cohort-specific rather than universally applicable. [158]C
Clinical burden and functional expression
Across gMG studies, clinically meaningful disease is captured not only by strength examination but also by patient-reported function, fatigue, and quality of life. Nipocalimab improved disease-related quality-of-life measures in the VIVACITY-MG3 analysis, which used MG-QoL15r, Neuro-QoL Fatigue, EQ-5D-5L, and patient global assessments. [100] Efgartigimod real-world evaluation in AChR-positive gMG used MG-ADL, QMG, and MG-QoL15r, while a predictive study defined minimal symptom expression as an MG-ADL score of 0 or 1, sustained for at least 4 consecutive weeks after treatment initiation. [153] [143] These measures help distinguish persistent generalized functional impairment from transient symptom fluctuation.
Hospital utilization is another marker of clinically consequential generalized disease. In VIVACITY-MG3, investigators assessed hospital admissions, emergency-department visits, and hospital days, and examined clinical and demographic predictors of high-utilization events. [116] Long-term Japanese surveillance similarly evaluated time to retreatment with IVIg, intravenous methylprednisolone, plasma exchange, or thymectomy because of progression or relapse, illustrating that recurrence and treatment dependence are important dimensions of the clinical phenotype. [95]
| Variant or domain | Defining or characteristic evidence | Relevant measures or considerations |
|---|---|---|
| Ocular MG | Weakness predominantly affecting ocular muscles; refractory cases remain therapeutically challenging. [157]C | Ptosis/diplopia phenotype; MG-ADL, QMG, and MGII used in refractory disease studies. [157]C |
| Generalized MG | Disease extending beyond ocular muscles; major trials include MGFA classes II–IV. [138] | MG-ADL, QMG, exacerbations, rescue therapy, fatigue, quality of life, admissions, and emergency visits. [100] [137] [116] |
| AChR-Ab-positive MG | Population in which complement activation is a key pathogenic mechanism and C5 inhibitors have been studied. [138] | Complement-directed therapies and AChR-specific comparative analyses. [138] [142] |
| Seronegative MG | Clinical/electrophysiologic postsynaptic MG without detectable antibodies to known targets. [141] | Diagnosis may rely on clinical features, electrophysiology, pharmacologic testing, and treatment response. [141] |
| Juvenile MG | MG diagnosed before adulthood. [158]C | Pediatric remission and postintervention status require age-specific assessment. [158]C |
Supportive Care and Complication Management
- ▸Impending crisis can be operationalized using rapid bulbar or respiratory progression over ≤2 weeks plus MGFA IVb, QMG bulbar score 3, respiratory score 2, or combined bulbar–respiratory score ≥4. [49]
- ▸IVIg, PLEX, immunoadsorption, and high-dose corticosteroids are described as standard crisis therapies; eculizumab or ravulizumab has been studied in refractory crisis, but supporting evidence is observational. [46]
- ▸IVIg carries thromboembolic risk, including DVT, PE, ischemic stroke, and myocardial infarction; SCIg may reduce risk through lower peak IgG concentrations, but evidence is not MG-specific. [145]
- ▸Perioperative planning is especially important in thymoma-associated MG and should address preoperative immunotherapy, postoperative exacerbation, and postoperative crisis risk. [93,94]
- ▸Checkpoint inhibitors may cause MG flares and immune-related adverse events in patients with preexisting MG and thymoma. [21]
Recognition and escalation of deterioration
Generalized MG can deteriorate into severe exacerbation or myasthenic crisis, particularly when bulbar or respiratory weakness progresses. Crisis and impending crisis require immediate assessment of airway protection, ventilatory function, secretion handling, swallowing, and the need for intensive or intermediate care; the German multicentre study describes standard crisis treatment as IVIg, plasma exchange (PLEX), immunoadsorption, and high-dose corticosteroids. [46]D In a randomized prospective study of 38 AChR-antibody-positive patients, impending myasthenic crisis was defined as rapid progression of bulbar or respiratory symptoms over ≤2 weeks plus at least one of the following: MGFA class IVb, QMG bulbar subscore 3, respiratory subscore 2, or combined bulbar–respiratory subscore ≥4. [49]
The available evidence supports individualized rescue selection rather than assuming that every patient will respond equally to IVIg. A French referral-centre cohort specifically evaluated predictors of non-response to first polyvalent IVIg in adults with generalized MG experiencing a first crisis or exacerbation; it notes that IVIg and PLEX have generally comparable efficacy in this setting but that poor IVIg response remains clinically relevant. [97] A 2026 systematic review and meta-analysis of randomized trials across autoimmune neurological disorders compared TPE with IVIg for effectiveness, safety, and economic outcomes, although the supplied abstract does not provide MG-specific pooled estimates. [89]
Rescue and rapid-acting therapies
Efgartigimod was prospectively compared with IVIg in AChR-antibody-positive patients with impending crisis, using efgartigimod 10 mg/kg weekly for 4 weeks; the study was single-centre, randomized, open-label, and included 21 patients in the efgartigimod arm. [49] In a prospective multicentre observational study, double-filtration plasmapheresis was administered as 3–5 sessions, whereas efgartigimod was given as 4 weekly infusions; outcomes included QMG and MG-ADL change immediately after treatment and at 1 month. [98]
IVIg also has longer-term real-world evidence: a Japanese post-marketing surveillance study followed patients with generalized MG who received initial IVIg across 316 facilities, assessing time to retreatment with IVIg, intravenous methylprednisolone, plasmapheresis, or thymectomy because of progression or relapse, as well as effectiveness, safety, and cost-effectiveness over 2 years. [95] Rescue therapy is increasingly considered within a broader treatment strategy because inebilizumab was evaluated for exacerbations and rescue-therapy use in the phase 3 MINT randomized trial, which enrolled participants internationally from August 2020 through November 2023 and had a 52-week randomized controlled period. [137]
For highly active AChR-positive disease, eculizumab has been assessed in routine practice. A multicentre cohort included 33 patients, comprising one early-onset case, 13 late-onset cases, and 19 thymoma-associated cases. [90]C Another real-world study evaluated eculizumab in refractory late-onset AChR-positive generalized MG, a population characterized by comorbidity-related limitations of conventional immunosuppression and increased crisis risk. [92]C In therapy-refractory crisis or severe exacerbation, a German multicentre series evaluated eculizumab or ravulizumab in AChR-antibody-positive patients with MGFA IVb/V treated in intensive or intermediate care. [46]D A separate emergency case series described four AChR-antibody-positive patients with five impending or manifest crisis episodes treated with eculizumab; none had received IVIg, PLEX, or FcRn inhibition during the preceding month. [41]C These data are observational or case-series evidence and should not displace established airway, ventilatory, and rescue-therapy support. [41]C[46]D
Thromboembolism and treatment safety
IVIg is associated with thromboembolic complications, including DVT, pulmonary embolism, ischemic stroke, and myocardial infarction. [145] A systematic review and narrative meta-synthesis found that subcutaneous immunoglobulin produces lower peak serum IgG concentrations and may confer lower thromboembolic risk than IVIg, although the evidence covered neurological and immunological indications broadly rather than MG alone. [145] Patients receiving IVIg should therefore have individualized assessment of thrombotic risk and monitoring for thromboembolic symptoms; the cited review does not establish SCIg as an acute crisis substitute. [145]
Perioperative and postoperative care
Thymoma-associated MG carries particular risk of postoperative deterioration. In a multicentre retrospective cohort of 347 patients with thymoma-associated MG, the primary outcome was acute exacerbation within 1 year after thymectomy, and the study examined whether longer preoperative immunotherapy reduced this risk. [93] A separate retrospective study of 78 generalized MG patients undergoing thymectomy compared conventional oral immunosuppression with rapid antibody-clearing strategies using lymphoplasmapheresis or efgartigimod; outcomes included postoperative exacerbation at 1 month, QMG and MG-ADL measures, operative variables, postoperative myasthenic crisis, and costs. [94]
Non-thymectomy surgery also warrants careful planning. In a propensity-matched national database analysis, MG patients undergoing lumbar interbody fusion, lumbar decompression, anterior cervical discectomy and fusion, or posterior cervical decompression and fusion were compared with non-MG patients for in-hospital and 90-day postoperative complications. [91] The analysis excluded patients with prior thymectomy and matched patients by age, sex, and comorbidity burden. [91]
Avoidance of iatrogenic worsening and follow-up
Immune checkpoint inhibitors can provoke immune-related adverse events and MG flares. In a retrospective cohort, six patients with preexisting MG and thymoma received checkpoint inhibitors and were compared with ten thymoma patients without MG; MG flares, immune-related adverse events, treatment outcomes, AChR-antibody levels, and thymoma pathology were assessed. [21]D Checkpoint inhibition therefore requires specialist risk–benefit assessment and close neuromuscular monitoring. [21]D
Longitudinal follow-up should include symptom burden, functional status, exacerbation history, and treatment toxicity. A bicentre cohort studied dynamic AChR-antibody monitoring after minimal symptom expression; exacerbation was defined as an MG-ADL increase of ≥2 points. [53] Population-based Ontario data quantified MG incidence, prevalence, crisis burden, mortality, healthcare utilization, costs, and treatment patterns from 2013–2020, while a Korean nationwide cohort assessed long-term mortality in incident MG diagnosed from 2005–2020. [146][96] The 2026 Taiwan clinical practice guideline used systematic review and a modified Delphi process involving 37 MG specialists and a patient representative to standardize management. [131]
| Clinical situation | Evidence-informed considerations |
|---|---|
| Impending crisis | Rapid bulbar or respiratory progression over ≤2 weeks with MGFA IVb, QMG bulbar score 3, respiratory score 2, or combined score ≥4. [49] |
| Crisis or severe exacerbation | Immediate respiratory and bulbar assessment; reported standard therapies include IVIg, PLEX, immunoadsorption, and high-dose corticosteroids. [46]D |
| Rescue treatment | IVIg and PLEX are established rescue approaches; efgartigimod, DFPP, and complement inhibition have been evaluated in newer comparative, observational, or emergency studies. [46]D[49][98] |
| IVIg safety | Monitor for thromboembolic complications; SCIg may have a lower thromboembolic risk, but comparative evidence is broad-indication evidence. [145] |
| Surgery | Assess postoperative exacerbation and crisis risk, particularly in thymoma-associated MG; studies evaluated preoperative immunotherapy and rapid antibody-clearing strategies. [93][94] |
Prognosis and Long-term Outcomes
- ▸Long-term burden is reflected in reduced HRQoL and health utility, with fatigue and depressive symptoms important contributors to disability. [106][112]
- ▸Nipocalimab and efgartigimod have been evaluated for sustained clinical response and patient-reported outcomes in randomized gMG studies lasting up to **24–26 weeks**. [100][101][102]
- ▸Cemdisiran, pozelimab, vemircopan, and eculizumab expand complement-directed treatment options, particularly for antibody-positive or refractory disease. [92][103][107][111]
- ▸Early low-dose rituximab may be steroid-sparing in selected AChR-antibody-positive gMG, but response is heterogeneous and evidence is observational. [114][115]
- ▸IVIg, perioperative antibody-clearing strategies, physical-activity and sleep interventions, and ketogenic diets may support disease management, although evidence varies from randomized trials to feasibility studies. [94][95][104][105]
- ▸CAR-based therapies remain investigational; available autoimmune-disease evidence is dominated by small studies and early clinical reports. [109][113]
Overall outlook
Myasthenia gravis (MG) remains a chronic, fluctuating autoimmune neuromuscular disorder in which prognosis is determined by disease distribution, antibody subtype, age at onset, comorbidity burden, treatment response, and occurrence of myasthenic crisis. The supplied updated evidence focuses primarily on generalized MG (gMG), treatment response, sustained disease control, health-related quality of life (HRQoL), and treatment safety rather than untreated natural history. [99][100][102][106]
Health-related impairment remains clinically important. A systematic review and meta-analysis of EQ-5D studies found that adults with MG have measurable reductions in health utility and self-rated health, although estimates varied according to population, instrument, tariff, and study design; the review included 10 studies and used random-effects methods with subgroup and sensitivity analyses. [106] Fatigue is a major contributor to long-term disability and is distinct from fatigable weakness. In a prospective study of clinically stable patients, depressive symptoms—but not obstructive sleep-apnea severity—were associated with general fatigue. [112]
Sustained disease control and quality of life
Novel therapies can improve patient-reported outcomes in addition to examination-based measures. In the phase 3 Vivacity-MG3 study, seropositive adults with gMG received nipocalimab or placebo alongside standard-of-care therapy for 24 weeks; prespecified outcomes included MG-QoL15r, Neuro-QoL Fatigue, EQ-5D-5L, and patient global assessments of fatigue. [100] Post hoc Vivacity-MG3 analyses specifically evaluated whether nipocalimab produced sustained responses over the same 24-week period, using meaningful clinical improvement, substantial improvement, and other response categories for MG-ADL and QMG scores. [102]
Efgartigimod also demonstrated efficacy across clinically relevant subgroups in the AChR-antibody-positive ADAPT population. Participants received four once-weekly infusions per treatment cycle over 26 weeks, and subgroup analyses examined MG-ADL and QMG responder rates during cycles 1 and 2 together with treatment-emergent adverse events. [101] A Bayesian network meta-analysis of randomized trials sought to compare generalized-MG treatments while accounting for differences between trial populations; it searched major databases through 2 May 2025 and included prospective studies of adults reporting treatment differences in MG-ADL outcomes. [99]
Targeted therapies and longer-term treatment implications
Complement-directed treatment remains particularly relevant to antibody-positive gMG. The phase 3 NIMBLE trial evaluated cemdisiran, an siRNA targeting complement C5, as monotherapy and in combination with the C5 antibody pozelimab in adults with generalized MG who were anti-AChR- or anti-LRP4-antibody positive and had baseline MG-ADL scores of ≥6. [103] Vemircopan was evaluated as an oral, selective factor-D inhibitor intended to block alternative-pathway complement activation while preserving classical and lectin pathway activity; the randomized trial enrolled adults with AChR-antibody-positive gMG. [107]
Real-world evidence suggests potential benefit in difficult-to-treat populations, but it is less definitive than randomized evidence. A retrospective study evaluated eculizumab in refractory late-onset, AChR-antibody-positive gMG, a population described as having immunosenescence, comorbidity-related treatment limitations, and high crisis risk; outcomes included clinical response, safety, and HRQoL. [92]C A prospective cohort of patients with poor early response to one efgartigimod cycle examined subsequent eculizumab treatment, enrolling 18 inadequate responders from an initially followed group of 103 patients. [111]C These findings support consideration of sequential treatment strategies but do not establish comparative long-term superiority. [111]C
IVIg continues to have a role in generalized disease. Japanese post-marketing surveillance across 316 facilities assessed two-year effectiveness, safety, and cost-effectiveness after initial IVIg exposure; the primary outcome was time to retreatment with IVIg, intravenous methylprednisolone, plasmapheresis, or thymectomy because of progression or relapse. [95] For patients undergoing thymectomy, a retrospective study of 78 individuals compared conventional oral immunosuppression with rapid antibody-clearing preparation using lymphoplasmapheresis or efgartigimod, assessing postoperative QMG, exacerbations, MG-ADL, postoperative crisis, surgical outcomes, and costs. [94]
Steroid-sparing and investigational approaches
Early low-dose rituximab may improve disease control and reduce corticosteroid exposure in selected non-thymomatous, immunosuppression-naïve, AChR-antibody-positive gMG. A retrospective South Wales cohort treated patients within 12 months of generalization with a single 500-mg infusion and assessed MGFA class, ADL, rescue treatment, prednisolone dose, and adverse events through more than 12 months. [114]C A separate retrospective study developed and validated a predictive model for minimal symptom expression after rituximab in AChR-antibody-positive MG, reflecting heterogeneous treatment response. [115]
Lifestyle interventions may influence long-term functioning, but current evidence is preliminary. A randomized pilot study assigned 41 adults with generalized MG to a ketogenic diet or habitual diet for 12 weeks, evaluating MG-ADL, QMG, MGFA class, fatigue, HRQoL, patient-acceptable symptom state, and immunological markers. [104]C The DIG-MG randomized feasibility trial used digital monitoring followed by 12 weeks of physical-activity guidance, sleep-hygiene education, or observation, with fatigue and MG-ADL as principal outcomes. [105]C
CAR-based cellular therapy remains investigational. A systematic review and meta-analysis assessed clinical remission, medication-free remission, and adverse events across autoimmune diseases, while another systematic review included 32 studies and 124 patients, with MG among the principal diseases represented. [109][113] These data are largely derived from small studies, case reports, and early clinical investigations and should not yet be interpreted as establishing durable MG remission. [109][113]
Prognostic cautions
Treatment decisions should balance sustained symptom control against infection, infusion, immunosuppression, and disease-specific risks. Complement inhibition has established clinical utility but may increase susceptibility to meningococcal infection; alternative-pathway inhibition is being developed partly to preserve other complement-mediated immune responses. [107] Rare immune-checkpoint-inhibitor-associated MG–myositis–myocarditis overlap can be life-threatening; a case report described successful rescue with eculizumab in tislelizumab-related overlap syndrome with dual AChR and titin antibody positivity, but case-level evidence cannot define general prognosis. [108] Overall, newer therapies offer increasing opportunities for sustained functional and HRQoL improvement, while the durability of benefit, optimal sequencing, and likelihood of medication-free remission remain incompletely defined. [99][100][102][103][106][109][111]C[113]
| Domain | Updated evidence | Prognostic interpretation |
|---|---|---|
| HRQoL and utility | EQ-5D systematic review/meta-analysis; nipocalimab HRQoL analysis | MG produces substantial patient-reported burden; targeted therapy may improve HRQoL. [100][106] |
| Sustained control | Nipocalimab analyses over 24 weeks; efgartigimod ADAPT over 26 weeks | Sustained response is measurable, but longer-term durability requires further study. [101][102] |
| Refractory or late-onset disease | Real-world eculizumab and sequential eculizumab-after-efgartigimod cohorts | Potential benefit exists, but observational designs limit causal inference. [92]C[111]C |
| Steroid-sparing therapy | Rituximab cohorts and response prediction model | May reduce treatment burden in selected patients; response is variable. [114]C[115] |
| Emerging strategies | Cemdisiran, vemircopan, CAR-based therapies, and lifestyle interventions | Promising but heterogeneous evidence; several approaches remain investigational. [103][104]C[105]C[107][109][113] |
Special Populations
- ▸Late-onset MG requires attention to comorbidity, immunosenescence, infection risk, and treatment tolerability; available studies include eculizumab and early low-dose rituximab cohorts. [92,114,149]
- ▸Thymoma-associated MG warrants coordinated oncologic, neurologic, embolization, and perioperative planning; rapid antibody-clearing strategies have been evaluated before thymectomy. [94,148]
- ▸Immune checkpoint inhibitor-associated MG may occur with myositis and myocarditis and can be fatal. [147]
- ▸Antibody assay methodology affects AChR and MuSK subgroup classification, while video-oculography and quantitative ultrasound remain investigational or adjunctive approaches. [117,150,151]
- ▸Targeted therapies and supportive delivery systems should be evaluated alongside quality of life, healthcare utilization, infection risk, and cost outcomes. [95,100,101,111,116,139,149]
Older and late-onset myasthenia gravis
Late-onset MG is clinically important because immunosenescence, comorbidity burden, and limited tolerance of conventional immunosuppression may complicate treatment; a 2026 study specifically evaluated eculizumab in patients with refractory, acetylcholine-receptor-antibody-positive generalized late-onset MG. [92]C In a separate South Wales retrospective cohort of non-thymomatous, immunosuppression-naive adults with generalized AChR-positive MG treated within 12 months of generalization, early low-dose rituximab consisted of a single 500-mg infusion; participants had a median age of 71 years, and outcomes included MGFA class, ADL, rescue therapy, prednisolone exposure, and adverse events. [114]C Low-dose rituximab safety data from a 186-patient real-world cohort showed infections in 15.59% during a median 2.41-year follow-up, with most infections occurring during the first treatment cycle; the study also assessed hypogammaglobulinemia and associated risk factors. [149]
Population-based Ontario data identified 2,601 people with MG, with a mean age of 65.7 years and 46.7% women; standardized incidence remained approximately 3.2–4.0 per 100,000 between 2013 and 2020. [146] The same study evaluated myasthenic crisis, mortality, survival, healthcare utilization, costs, and treatment patterns, including publicly insured patients aged 65 years or older. [146] Korean nationwide data likewise examined autoimmune diseases during the 10 years preceding MG diagnosis, using matched controls, and specifically assessed autoimmune thyroid disease and other autoimmune comorbidity patterns. [120]
Serologic and clinical subgroups
The ADAPT subgroup analysis evaluated efgartigimod across a broad population of AChR-antibody-positive adults with generalized MG receiving at least one stable background treatment. Efgartigimod was administered as four once-weekly infusions per cycle over 26 weeks, with subgroup outcomes based on MG-ADL and QMG responder rates in cycles 1 and 2 and treatment-emergent adverse events. [101] Diagnostic antibody testing is also relevant to subgroup classification: the prospective ADAM study compared live cell-based assays, fixed cell-based assays, and indirect ELISA for AChR and MuSK antibodies in adults and children evaluated for suspected MG. [150]
Thymoma-associated MG and perioperative care
Thymoma-associated MG represents a distinct setting in which tumor biology, autoimmunity, and perioperative neurologic risk intersect. [148] In a single-center retrospective cohort of 64 patients with thymoma-associated MG who underwent clinically indicated preoperative embolization followed by thymectomy between 2018 and 2025, angiographic tumor-blush reduction was evaluated against tumor necrosis, HIF-1α expression, and CD163-positive macrophages. [148] A separate retrospective study of 78 generalized-MG patients undergoing thymectomy compared oral immunosuppressants with rapid antibody-clearing therapy using lymphoplasmapheresis or efgartigimod; outcomes included 3-month postoperative QMG, postoperative exacerbation, MG-ADL, surgical outcomes, postoperative myasthenic crisis, and perioperative costs. [94]
Long-term thymectomy counseling should distinguish MG-related surgical indications from general adult thymectomy outcomes. A propensity-score-matched retrospective study compared 425 adults undergoing thymectomy with patients undergoing comparator cardiothoracic procedures, with follow-up extending to 10 years and outcomes including all-cause mortality, new malignancy, and autoimmune disease. [121]
Immune checkpoint inhibitor-associated MG
Immune checkpoint inhibitor-related overlap of MG, myositis, and myocarditis is rare but potentially fatal. A 2026 systematic review and pooled individual-case analysis combined published case reports and series with three additional institutional patients; the primary outcome was all-cause in-hospital mortality, and regression analyses explored mortality-associated factors. [147]C Patients receiving immune checkpoint inhibitors who develop weakness, ocular or bulbar symptoms, muscle injury, or cardiac manifestations therefore require evaluation for this multisystem overlap rather than isolated MG alone. [147]C
Refractory disease and targeted therapies
For patients with inadequate early response to efgartigimod, a prospective real-world cohort followed 103 generalized-MG patients through one treatment cycle and identified 18 poor early responders for evaluation of subsequent eculizumab treatment. [111]C Eculizumab was also studied in refractory late-onset AChR-positive generalized MG, with assessment of clinical outcomes, safety, and quality of life. [92]C Predictive modeling research has attempted to identify AChR-positive patients most likely to achieve minimal symptom expression after low-dose rituximab, using retrospective data from treatment between 2019 and 2025 and logistic-regression-based model development and validation. [115]
Quality of life, healthcare burden, and treatment delivery
In VIVACITY-MG3, seropositive adults with generalized MG received nipocalimab plus standard care or placebo plus standard care for 24 weeks; prespecified patient-reported outcomes included MG-QoL15r, Neuro-QoL Fatigue, EQ-5D-5L, and patient global fatigue measures. [100] The same trial supported post-hoc analyses of hospital admissions, emergency-department visits, hospital days, predictors of high-cost events, and US hospital costs per patient-year. [116] Japanese post-marketing surveillance followed patients receiving IVIg for up to 2 years, evaluating time to retreatment or other progression-related intervention, long-term safety, effectiveness, and cost-effectiveness. [95]
Patients and caregivers may be able to administer injectable treatment using either an autoinjector or a prefilled syringe with needle-safety device: in a randomized human-factors study without device-use training, 94% successfully completed the simulated-use scenario. [139] Device selection should still account for patient, caregiver, and healthcare-professional technique and the intended use environment. [139]
Diagnostic and supportive considerations
Video-oculographic repetitive saccadic-fatigability testing was prospectively evaluated in patients with MG, unilateral third-, fourth-, or sixth-nerve palsy, and healthy controls undergoing 75 repetitive horizontal and vertical saccades; the study assessed changes in saccadic range and target-acquisition time to distinguish MG-related diplopia from unilateral ocular motor palsy. [117] Quantitative muscle ultrasound was explored in a pilot retrospective study of 18 patients with acquired or genetic neuromuscular-junction disorders, including MG, to assess structural muscle changes alongside electrodiagnostic testing. [151]C During septic shock, terminal complement inhibition was studied in a global propensity-score-matched cohort of adults with underlying indications including MG; outcomes included renal, hematologic, and thrombotic complications. [152]
| Population or issue | Evidence and clinically relevant outcomes |
|---|---|
| Older or late-onset MG | Eculizumab was studied in refractory late-onset AChR-positive generalized MG; early low-dose rituximab was evaluated in patients with median age 71 years. [92]C[114]C |
| Rituximab safety | In a 186-patient cohort, infections occurred in 15.59% over a median 2.41 years; hypogammaglobulinemia was also assessed. [149] |
| Thymoma-associated MG | Studies evaluated preoperative embolization biology and rapid antibody clearance before thymectomy. [94][148] |
| ICI-associated MG | MG–myositis–myocarditis overlap is rare and potentially fatal; pooled case data evaluated in-hospital mortality. [147]C |
| Treatment response | Efgartigimod subgroup efficacy, eculizumab after poor efgartigimod response, and prediction of low-dose rituximab response have been studied. [101][111]C[115] |
| Patient burden | Nipocalimab studies assessed HRQoL, hospital utilization, emergency visits, hospital days, and costs; IVIg surveillance assessed 2-year outcomes and cost-effectiveness. [95][100][116] |
Guidelines and Resources
- ▸The 2020 International Consensus Guidance remains a central international management framework and was developed using the RAND/UCLA appropriateness method.[136]
- ▸For nonthymomatous AChR-antibody-positive generalized MG in patients younger than 65 years, thymectomy plus prednisone improved outcomes versus prednisone alone in a Class I study.[83]
- ▸IVIG and plasma exchange are recommended short-term therapies for acute exacerbations or severe MG; the cited EFNS IVIG guidance assigns level A evidence to these indications.[87]
- ▸Diagnosis should combine fatigable weakness with antibody testing and/or neurophysiologic assessment.[127]
- ▸Thymoma is associated with MG and requires multidisciplinary thymic-tumor management and surveillance.[80]
- ▸Minimal manifestations or better is an important treatment goal used in consensus-based outcome assessment.[129,134,135]
- ▸Botulism can mimic acute neuromuscular-junction disease and causes descending paralysis through inhibition of acetylcholine release.[79]
Core management guidance
The principal international framework is the International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update, developed by an international expert panel using the RAND/UCLA appropriateness method and addressing seven treatment topics.[136]D The Association of British Neurologists guideline aims to combine evidence-based recommendations with established best practice where evidence is limited and advises clinicians to seek specialist opinion when management choices cannot be resolved from evidence alone.[132] The 2022 Japanese guideline revised MG diagnostic criteria, defined refractory MG, incorporated molecular-targeted therapies, divided MG into six clinical subtypes, and supplied treatment algorithms for MG and Lambert–Eaton myasthenic syndrome (LEMS).[133] The 2025 Portuguese consensus guideline describes MG diagnosis as based on fatigable weakness, supported by neurophysiologic testing and/or detection of pathogenic antibodies, including antibodies against the acetylcholine receptor (AChR) and, less frequently, muscle-specific kinase (MuSK).[127] Taiwan’s clinical practice guideline was developed by 37 MG specialists and a patient representative after literature review covering 2015–2024 and a modified Delphi process; it addresses diagnosis and treatment in the context of increasing generalized MG prevalence and healthcare utilization in Taiwan.[131]
Diagnosis, crisis, and acute treatment
MG diagnosis should be integrated with the clinical finding of fatigable weakness, antibody testing, and neurophysiologic assessment rather than relying on a single test.[127] The 2007 AAN evidence report on ocular MG systematically reviewed medical treatments for ocular disease, but that report is explicitly retired and should not be treated as a current standalone guideline.[82] Earlier European guidance recommended anticholinesterase medication as initial MG treatment, with caution in MuSK-antibody disease, and recommended plasma exchange in severe disease or before surgery.[84] The 2006 European guideline similarly placed anticholinesterase drugs first and considered plasma exchange a short-term treatment for severe MG and a preoperative intervention.[85]
IVIG and plasma exchange are established short-term therapies for acute exacerbations and severe MG in the cited European neurological guidance; the EFNS IVIG guideline classified IVIG for acute MG exacerbations and short-term treatment of severe MG as a level A recommendation.[87] A Canadian evidence-based guideline likewise addressed IVIG use across 22 neurologic conditions and was developed in response to substantial growth in IVIG utilization, including off-label use.[88] A later review of IVIG guidance reiterates level A effectiveness for acute MG exacerbations and short-term treatment of severe MG.[128]
Botulism is an important diagnostic and treatment-related differential because botulinum neurotoxin blocks acetylcholine release at the neuromuscular junction and causes potentially life-threatening flaccid descending paralysis beginning with cranial nerve palsies and possibly progressing to limb weakness and respiratory failure.[79] The 2021 US botulism guideline describes foodborne, wound, infant, adult intestinal-colonization, and iatrogenic botulism, including illness after high-concentration cosmetic or therapeutic toxin injections.[79]
Thymectomy and thymic disease
For patients younger than 65 years with nonthymomatous, AChR-antibody-positive generalized MG, the AAN practice advisory found that oral prednisone plus thymectomy produced better clinical outcomes than prednisone alone in a Class I study, including a greater probability of achieving minimal-manifestation status.[83] This recommendation applies specifically to the studied AChR-positive generalized population and should not automatically be extrapolated to MuSK-positive disease, purely ocular MG, or thymoma-associated MG.[83]
Thymoma is associated with autoimmune paraneoplastic diseases such as MG, whereas these disorders typically do not occur with thymic carcinoma.[80] The NCCN guideline recommends diagnosis, treatment, and surveillance planning for thymomas and thymic carcinomas through a multidisciplinary team experienced in these uncommon mediastinal tumors.[80] In suspected paraneoplastic neurologic disease, the EFNS task force recommends tumor screening as soon as possible because the neurologic syndrome often precedes malignancy detection and the tumor affects prognosis and treatment; thymoma is among the malignancies considered in relation to MG.[86]
Treatment goals, outcomes, and refractory disease
International consensus-based care commonly uses MGFA post-intervention status, with minimal manifestations or better serving as an important treatment goal.[129][134][135] In a large Japanese analysis, investigators evaluated clinical metrics intended to reduce ambiguity in assigning minimal-manifestation status, using 3,800 MG patients overall and 2,784 patients with generalized MG.[134] A Duke MG Clinic retrospective cohort followed patients for at least 2 years and analyzed outcomes under International Consensus Guidance-based care, including time to treatment goals and post-intervention status.[129] Comorbid diseases may influence clinical outcomes, and one observational study evaluated comorbidity patterns across six MG subgroups defined by antibodies, age at onset, and thymoma status.[135] The Japanese revision specifically defines refractory MG and includes molecular-targeted drugs in its treatment framework.[133] A 2024 retrospective study of 116 patients assessed serial antibody-concentration ratios as a possible marker of treatment-refractory MG, using International Consensus Guidance criteria as the reference standard; this remains observational diagnostic research rather than a treatment guideline.[130]
Special circumstances and resource links
During the COVID-19 outbreak, French neuromuscular-network guidance recommended reserving hospitalization for emergencies, nondeferrable treatment, evaluations whose delay could compromise survival, and cardiorespiratory assessments for which delay might be harmful.[126] This pandemic-specific document is a contingency resource rather than a general MG treatment standard.[126]
Clinicians should therefore use current consensus and national guidelines for routine management, apply disease subtype and antibody status when interpreting recommendations, involve experienced multidisciplinary teams for thymic disease, and use IVIG or plasma exchange for appropriately selected severe or exacerbated cases.[80][83][87][127][132][136]D
| Domain | Key resource or recommendation | Evidence/reference |
|---|---|---|
| International MG management | 2020 consensus guidance covering seven treatment topics | [136]D |
| National MG guidance | British, Japanese, Portuguese, and Taiwanese diagnostic and treatment frameworks | [127,131-133] |
| Thymectomy | Consider in appropriately selected nonthymomatous AChR-positive generalized MG, particularly under 65 years | [83] |
| Acute severe MG | IVIG and plasma exchange for exacerbation or short-term severe disease treatment | [84][87][88][128] |
| Thymic tumors | Multidisciplinary diagnosis, treatment, and surveillance; assess MG association | [80] |
| Paraneoplastic screening | Prompt tumor screening when a paraneoplastic neurologic syndrome is suspected | [86] |
| Differential diagnosis | Botulism causes toxin-mediated descending paralysis and impaired acetylcholine release | [79] |
| Pandemic contingency care | Reserve hospitalization for emergencies and nondeferrable or high-risk assessments | [126] |
References
- [1]
Miegel L, Hickstein J, Reibelt A et al.. “Myasthenia gravis and pregnancy: a systematic review and meta-analysis.” Journal of neurology (2026). PMID: 41787190 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Special Populations - [2]
Gilhus NE. “Myasthenia Gravis With Acetylcholine Receptor Antibodies in the Very Old: Treatment Challenges and Diagnostic Pitfalls.” European journal of neurology (2026). PMID: 41721543 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes, Special Populations - [3]
Pupillo E, Leone MA, Amato A et al.. “Prevalence and trajectories of post-COVID-19 neuromuscular conditions: A systematic-review and meta-analysis.” Journal of the neurological sciences (2026). PMID: 41494305 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [4]
Yakubu AO, Lawal FI, Nwaze CE et al.. “Sleep disorders in myasthenia gravis: A systematic review on prevalence, clinical associations, and the accuracy of assessment methodologies.” Sleep medicine (2026). PMID: 41418342 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes - [5]
Remijn-Nelissen L, Bakker WR, van Gelder T et al.. “Efficacy and Safety of Amifampridine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.” Neurology (2026). PMID: 41945880 ↗
L1bRCTCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes, Special Populations - [6]
Wu J, Eriksson-Dufva A, Budzianowska A et al.. “Rituximab in New-Onset Generalized Myasthenia Gravis: Long-Term Follow-Up of the RINOMAX Clinical Trial.” European journal of neurology (2025). PMID: 41194516 ↗
L1bRCTCited in: Epidemiology and Risk Factors - [7]
Huang X, Wang X, Yang Y et al.. “Assessing the potential causal influence of myasthenia gravis on neurodegenerative diseases via multivariable Mendelian randomization.” Medicine (2025). PMID: 41261682 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [8]
Kemchoknatee P, Pakaymaskul P, Piyawanarat N et al.. “Association Between Serum Anti-Acetylcholine Receptor (AChR-Ab) Titers and Clinical Outcomes in Patients with Ocular-Onset Myasthenia Gravis: An Academic Retrospective Cohort Study.” Clinical ophthalmology (Auckland, N.Z.) (2026). PMID: 41926519 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Clinical Features and Variants - [9]
Li Y, Tao Y, Zhao Z et al.. “Long COVID as an independent predictor of myasthenia gravis exacerbation: A prospective cohort study integrating machine learning for risk stratification.” Respiratory medicine (2026). PMID: 41319836 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [10]
Chen J, Su C, Feng L et al.. “Effects of Thymectomy in Late-Onset Myasthenia Gravis: A Multi-Center Longitudinal Retrospective Study.” Annals of neurology (2026). PMID: 41283202 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [11]
Pardo K, Kab T, Hellmann MA et al.. “Increased Prevalence of Extrathymic Neoplasms in Myasthenia Gravis Patients-A Population-Based, Matched Case-Control Study.” Muscle & nerve (2026). PMID: 41795172 ↗
L3bCASE_CONTROLCited in: Epidemiology and Risk Factors - [12]
Shihada K, Gorenshtein A, Wolfe GI et al.. “Urinary dysfunction in myasthenia Gravis: a cross-sectional case-control study.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 41483344 ↗
L3bCASE_CONTROLCited in: Epidemiology and Risk Factors - [13]
Kwon S, Park YB, Han KD et al.. “Association between obesity and subsequent risk of myasthenia gravis: a nationwide population-based cohort study.” Acta neurologica Belgica (2026). PMID: 41824214 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [14]
Leiva-Murillo EA, Martínez-Hernández E, Aldecoa I et al.. “Case Report: Thymoma-associated myasthenia gravis, myositis, myocarditis, and anti-GAD65 autoimmune encephalitis: a unique case of paraneoplastic polyautoimmunity.” Frontiers in immunology (2026). PMID: 41743715 ↗
L4CASE_REPORTCited in: Epidemiology and Risk Factors - [15]
Yan VKC, Xu W, Taniguchi Y et al.. “Myasthenia gravis following the initiation of statin therapy: A multinational self-controlled case series study.” Journal of internal medicine (2026). PMID: 41645666 ↗
L4CASE_REPORTCited in: Epidemiology and Risk Factors - [16]
Hu C, Liu S, Xi C et al.. “Sugammadex versus Neostigmine Reversal After Thoracoscopic Thymectomy in Myasthenia Gravis: A Multicenter, Randomized Controlled Trial.” Drug design, development and therapy (2025). PMID: 41488758 ↗
L1bRCTCited in: Epidemiology and Risk Factors - [17]
Dong H, Li M, Ma M et al.. “Clinical Characteristics of Childhood-Onset Myasthenia Gravis in a Large Chinese Cohort.” Pediatric neurology (2026). PMID: 41974154 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [18]
Cao L, Wang Y, Dai P et al.. “Neurotoxicity of immune checkpoint inhibitors: a retrospective pharmacovigilance study using FAERS database.” Frontiers in immunology (2026). PMID: 41972167 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [19]
D'Amico F, Campo S, Rini N et al.. “Efgartigimod in Patients with Generalized Myasthenia Gravis Refractory or Intolerant to IVIg.” Neurology and therapy (2026). PMID: 41922674 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Clinical Features and Variants - [20]
Fornaro M, Di Lorenzo C, Steardo L et al.. “Prevalence and outcomes of co-occurring psychiatric and neurological disorders: An atlas based on umbrella review of 81 meta-analyses.” European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology (2026). PMID: 41895003 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [21]
Sun C, Guo R, Yin X et al.. “Immune-related adverse events in patients with preexisting myasthenia gravis and thymoma following immune checkpoint inhibitor treatment: a retrospective, observational study.” Frontiers in immunology (2026). PMID: 41884848 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [22]
Masuda H, Uzawa A, Shibata M et al.. “Headache prevalence and types in multiple sclerosis and related neuroimmunological diseases: A multicenter study.” Cephalalgia : an international journal of headache (2026). PMID: 41883304 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [23]
Khateb M, Almasri A, Barnett-Tapia C et al.. “The Effect of Thymectomy on the Incidence of Extrathymic Cancers and Autoimmune Diseases in Patients With Non-Thymomatous Myasthenia Gravis.” Muscle & nerve (2026). PMID: 41862279 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [24]
Atula S, Piehl F, Schager I et al.. “Comorbidities and Treatment Patterns in People With Myasthenia Gravis in Denmark, Finland and Sweden: A Population-Based Observational Study.” Muscle & nerve (2026). PMID: 41834075 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [25]
He D, Yan C, Wang B et al.. “Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long-Term Real-World Study.” European journal of neurology (2026). PMID: 41823508 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [26]
Filippakopoulou E, Gavriilaki M, Arnaoutoglou M et al.. “Efficacy and safety of complement inhibitors and FcRn blockers in generalized AChR antibody-positive myasthenia gravis: a meta-analysis.” Journal of neurology (2026). PMID: 41925914 ↗
L2aSR_OBSCited in: Clinical Features and Variants - [27]
Zhong X, Xie Y, Li Y et al.. “Efficacy and safety of immunosuppressants and immunomodulators in juvenile myasthenia gravis: a systematic review and meta-analysis.” Journal of translational medicine (2026). PMID: 41772612 ↗
L2aSR_OBSCited in: Clinical Features and Variants, Prognosis and Long-term Outcomes, Special Populations - [28]
Oeztuerk M, Huntemann N, Gerischer L et al.. “Early versus late add-on therapy in generalized myasthenia gravis: a multicenter real-world cohort study.” Journal of neurology (2026). PMID: 41760990 ↗
L2bCOHORTCited in: Clinical Features and Variants, Prognosis and Long-term Outcomes, Special Populations - [29]
Zhou Q, Ouyang Y, Jiang F et al.. “Differential response to ofatumumab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study.” Therapeutic advances in neurological disorders (2026). PMID: 41726319 ↗
L2bCOHORTCited in: Clinical Features and Variants - [30]
Lin J, Chang T, Xiao L et al.. “Rapid efficacy of efgartigimod for generalized myasthenia gravis patients in acute exacerbations/worsening: multicenter real-world retrospective study.” Journal of neurology (2026). PMID: 41699286 ↗
L2bCOHORTCited in: Clinical Features and Variants, Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations - [31]
Hoffmann S, Zhao S, Callewaert F et al.. “Post Hoc, Sex-Specific Subgroup Analysis of Efgartigimod in Patients With Generalized Myasthenia Gravis From the ADAPT Trial: A Sex and Gender Equity in Research (SAGER) Guidelines Approach.” Muscle & nerve (2026). PMID: 41517964 ↗
L1bRCTCited in: Clinical Features and Variants, Prognosis and Long-term Outcomes, Special Populations - [32]
Fedak RR, Ruggerie RN, Shan Y et al.. “BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial.” Nature medicine (2026). PMID: 41514039 ↗
L1bRCTCited in: Clinical Features and Variants - [33]
Abuhammad A, Ayyad M, Albandak M et al.. “Double-seronegative myasthenia gravis: clinical characteristics, treatment, and outcomes - a systematic review of case reports and case series.” BMC neurology (2026). PMID: 41559594 ↗
L2aSR_OBSCited in: Clinical Features and Variants, Supportive Care and Complication Management - [34]
Ruan Z, Ning F, Zhang W et al.. “Single-cell profiling of immune reset in patients with refractory generalized myasthenia gravis receiving autologous CD19/BCMA CAR-T cell therapy.” Med (New York, N.Y.) (2026). PMID: 41747738 ↗
L2bTRIAL_NONRANDOMCited in: Clinical Features and Variants, Special Populations - [35]
Chuenkongkaew W, Chirapapaisan N, Chatchutimakorn P et al.. “Factors Influencing the Conversion of Ocular Myasthenia Gravis to Generalized Myasthenia Gravis: A Retrospective Cohort Study.” Journal of ophthalmology (2026). PMID: 41684543 ↗
L2bCOHORTCited in: Clinical Features and Variants - [36]
Meisel A, Uzawa A, Qi CZ et al.. “Minimal Symptom Expression in Generalized Myasthenia Gravis: A Valuable Patient-Centric Treatment Goal.” European journal of neurology (2026). PMID: 41853948 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Variants - [37]
Sanders DB, Lutz MW, Raja SM et al.. “The Duke MG Patient Registry III. Comparative Effectiveness of Azathioprine and Mycophenolate Mofetil in Generalized Myasthenia Gravis, a Retrospective Single Center Review.” Muscle & nerve (2026). PMID: 41700316 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Variants, Special Populations - [38]
Mansour GK, Alangari L, Khosyfan L et al.. “Efgartigimod for Generalized Myasthenia Gravis and Beyond: A Narrative Review of Its Pharmacological Profile, Clinical Utility, and Expanding Applications.” Biomedicines (2025). PMID: 41462987 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Variants - [39]
Qaqish A, Al Anber A, Abdelhafez G. “Late-Onset Ocular Myasthenia Gravis-Like Symptoms During Erenumab Therapy for Chronic Migraine: A Case Report.” Biologics : targets & therapy (2026). PMID: 41808843 ↗
L4CASE_REPORTCited in: Clinical Features and Variants - [40]
Itagaki Y, Iguchi M, Hattori K et al.. “Zilucoplan is effective for ravulizumab-refractory generalized myasthenia gravis with the C5 p.Arg885His variant: a case report.” Neuromuscular disorders : NMD (2026). PMID: 41771246 ↗
L4CASE_REPORTCited in: Clinical Features and Variants - [41]
Huang Y, Xiong Y, Zhan H et al.. “Emergency use of eculizumab in impending and manifest myasthenic crisis: a retrospective case series.” Therapeutic advances in neurological disorders (2026). PMID: 41769309 ↗
L4CASE_REPORTCited in: Clinical Features and Variants, Supportive Care and Complication Management - [42]
Shi S, Zhang Y, Yang W et al.. “Safety and Effectiveness of Eculizumab in Patients With Refractory Ocular or Ocular-Predominant Myasthenia Gravis: A Case Series.” Muscle & nerve (2026). PMID: 41741023 ↗
L4CASE_REPORTCited in: Clinical Features and Variants - [43]
Cao XG, Ni JX, Zhu XF et al.. “COVID-19-associated delayed-onset MuSK-positive myasthenia gravis presenting solely with respiratory failure: a case report.” Frontiers in immunology (2025). PMID: 41476989 ↗
L4CASE_REPORTCited in: Clinical Features and Variants, Supportive Care and Complication Management - [44]
Samara VC, Thottempudi N, Franke O et al.. “Novel Therapies for Generalized Myasthenia Gravis: Insights Into FcRn and Complement Inhibition.” American journal of therapeutics (Unknown). PMID: 41505161 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Variants - [45]
Liu ZH, Duan LM, Fang XZ et al.. “Efgartigimod as Rescue Therapy for PD-1 Inhibitor-Associated Myasthenia Gravis, Myocarditis, and Myositis (MMM) Syndrome: A 2-Case Report and Literature Review.” The American journal of case reports (2026). PMID: 41989988 ↗
L4CASE_REPORTCited in: Clinical Features and Variants - [46]
Gerischer L, Stein M, Schneider A et al.. “Complement Inhibition Therapy in Myasthenic Crisis-A Multicentre Retrospective Analysis of 17 Cases From Germany.” European journal of neurology (2026). PMID: 41983870 ↗
L5OTHERCited in: Clinical Features and Variants - [47]
Vesperinas A, Rocaspana-Codana J, Reyes-Leiva D et al.. “Digital Monitoring of Patients with Generalized Myasthenia Gravis: A Prospective Pilot Study.” Neurology and therapy (2026). PMID: 41957339 ↗
L5OTHERCited in: Clinical Features and Variants - [48]
Vissing J, Zimprich F, Atula S et al.. “A Delphi consensus on integrating novel therapies into the management of generalized myasthenia gravis.” Therapeutic advances in neurological disorders (2026). PMID: 41947805 ↗
L5OTHERCited in: Clinical Features and Variants - [49]
Li N, Zhang Y, Liu L et al.. “Efficacy and safety of efgartigimod in the treatment of impending myasthenic crisis.” Frontiers in immunology (2026). PMID: 41909657 ↗
L1bRCTCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations - [50]
Itagaki H, Hagino T, Endo T. “Takotsubo cardiomyopathy in myasthenia gravis: a systematic review of case reports with subtype-based analysis.” International journal of emergency medicine (2026). PMID: 41680628 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [51]
Chung CC, Wu IC, Bamodu OA et al.. “Machine Learning in Myasthenia Gravis: A Systematic Review of Prognostic Models and AI-Assisted Clinical Assessments.” Diagnostics (Basel, Switzerland) (2025). PMID: 40870896 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [52]
Çipi F, Koloneci C, Marku A et al.. “Health economic evaluations of myasthenia gravis: a systematic review.” Croatian medical journal (2026). PMID: 41520205 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [53]
He D, Chen H, Zhong H et al.. “Predictors of exacerbation in myasthenia gravis after minimal symptom expression: a bicenter cohort study.” Frontiers in immunology (2026). PMID: 41972143 ↗
L2bCOHORTCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations - [54]
Alvarez-Ortega AC, Padilla-Londoño N, Posso-Nuñez JA et al.. “Clinical outcomes and follow-up after thymectomy in patients with myasthenia gravis: A Colombian cohort study.” JTCVS open (2026). PMID: 41960072 ↗
L2bCOHORTCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [55]
Huan X, Chen R, Jin L et al.. “1-Year Clinical Outcome Post-Myasthenic Crisis: A Multicenter Prospective Study in China.” European journal of neurology (2026). PMID: 41589418 ↗
L2bCOHORTCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations - [56]
Juel VC. “Autoimmune Myasthenia Gravis.” Continuum (Minneapolis, Minn.) (2025). PMID: 41037173 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [57]
Guo R, Sun C, Huang X et al.. “Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: A retrospective cohort study.” Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (2025). PMID: 40914739 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [58]
Arrese L, Di Meglio M, Byrne L et al.. “Swallowing Impairments in Patients with Myasthenia Gravis: A Scoping Review.” Dysphagia (2025). PMID: 41361129 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [59]
Woo J, Kim SW, Kim JH et al.. “Identification of High-Risk Population for Mortality and Severe Clinical Outcomes Among Patients With Myasthenia Gravis: A Nationwide Population-Based Cohort Study in Korea.” Journal of Korean medical science (2025). PMID: 40985852 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [60]
Manolopoulos A, Alzuabi M, Elmashala A et al.. “Immunoglobulin for myasthenia gravis.” The Cochrane database of systematic reviews (2025). PMID: 41090479 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [61]
Mitsutake A, Suzuki A, Murai H et al.. “Myasthenic crisis associated with invasive thymoma successfully treated with ravulizumab: A case series.” Journal of the neurological sciences (2025). PMID: 41274033 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [62]
Ren L, Wei L, Jiang S et al.. “Efgartigimod for patients with thymoma associated generalized myasthenia gravis during the perioperative period: a four-case report.” Frontiers in immunology (2025). PMID: 41112289 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [63]
Sobieszczuk E, Szczudlik P, Barańska J et al.. “Therapeutic approach to myasthenia gravis treatment in the era of new biologics - review of existing and upcoming therapies.” Neurologia i neurochirurgia polska (2026). PMID: 41954011 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [64]
Alhammadi S, Chalk C. “Preoperative Management of Patients With Myasthenia Gravis: A Review of the Evidence.” The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques (2026). PMID: 41495972 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [65]
Remijn-Nelissen L, Bakker WR, van den Hout WB et al.. “Efficacy of Pyridostigmine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.” Neurology (2026). PMID: 41945881 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes, Special Populations - [66]
Dummer R, Guo J, Luke JJ et al.. “Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study.” The Lancet. Oncology (2026). PMID: 41698381 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes, Special Populations - [67]
Vu T, Durmus H, Rivner M et al.. “BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.” Nature medicine (2026). PMID: 41514038 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes - [68]
Sousa CDF, Terroba-Navajas P, Tzartos J et al.. “Humoral correlates of clinical response to thymectomy in myasthenia gravis.” Journal of autoimmunity (2026). PMID: 41411760 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes - [69]
Fan M, Zhang H, Shi Y et al.. “The prognosis of MG patients with different thymic pathology: a multicenter retrospective cohort study.” BMC medicine (2025). PMID: 41402829 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [70]
Sandhu S, Joshua AM, Emmett L et al.. “[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.” The Lancet. Oncology (2026). PMID: 41926961 ↗
L2bTRIAL_NONRANDOMCited in: Prognosis and Long-term Outcomes, Special Populations - [71]
Leclercq C, Archer A, Ceccone F et al.. “Combined adapted physical activity and art-therapy intervention in myasthenia gravis: Study protocol for a randomized crossover pilot trial.” Contemporary clinical trials (2026). PMID: 41720335 ↗
L2bTRIAL_NONRANDOMCited in: Prognosis and Long-term Outcomes - [72]
Barnawi AB, Hajjar WM, Almaymuni AD et al.. “Comparative outcomes of robotic- and video-assisted thoracoscopic surgery in thymectomy: a systematic review of implications for myasthenia gravis remission and long-term oncology.” Journal of thoracic disease (2026). PMID: 41660448 ↗
L2aSR_OBSCited in: Prognosis and Long-term Outcomes - [73]
Sun S, Zhang Y, Ma J et al.. “Clinical characteristics and treatment outcomes in thymoma- related aplastic anemia: a case report and literature review.” Journal of cardiothoracic surgery (2026). PMID: 41622196 ↗
L2aSR_OBSCited in: Prognosis and Long-term Outcomes - [74]
Tammam G, Villa L, Lemmers RJLF et al.. “Co-Occurrence of Myasthenia Gravis and Facioscapulohumeral Muscular Dystrophy: A Case Series and Review of Literature.” European journal of neurology (2026). PMID: 41542987 ↗
L4CASE_REPORTCited in: Special Populations - [75]
Kab T, Pardo K, Hellmann MA et al.. “Risk of New-Onset Myasthenia Gravis Following COVID-19 Infection and Vaccination: A Population-Based Case-Control Study.” European journal of neurology (2026). PMID: 41854135 ↗
L3bCASE_CONTROLCited in: Special Populations - [76]
Rotstein DL, Alroughani R, Arrambide G et al.. “Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGAD.” The Lancet. Neurology (2026). PMID: 41722595 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [77]
Nielsen JJJ, Levison LS, Andersen H. “Associated Autoimmunity in Myasthenia Gravis in Denmark: A Nationwide Case-Control Study.” European journal of neurology (2026). PMID: 41669887 ↗
L3bCASE_CONTROLCited in: Special Populations - [78]
Lei P, Lu Y, Xia J et al.. “Efgartigimod for steroid-resistant autoimmune glial fibrillary acidic protein astrocytopathy: a case report and literature review.” Journal of neuroimmunology (2026). PMID: 41610721 ↗
L4CASE_REPORTCited in: Special Populations - [79]
Rao AK, Sobel J, Chatham-Stephens K et al.. “Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021.” MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports (2021). PMID: 33956777 ↗
L1cGUIDELINECited in: Guidelines and Resources - [80]
Riely GJ, Wood DE, Loo BW et al.. “Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 40499586 ↗
L1cGUIDELINECited in: Guidelines and Resources - [81]
Murray MJ, DeBlock H, Erstad B et al.. “Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient.” Critical care medicine (2016). PMID: 27755068 ↗
L1cGUIDELINECited in: Guidelines and Resources - [82]
Benatar M, Kaminski HJ. “Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology [RETIRED].” Neurology (2007). PMID: 17460154 ↗
L1cGUIDELINECited in: Guidelines and Resources - [83]
Gronseth GS, Barohn R, Narayanaswami P. “Practice advisory: Thymectomy for myasthenia gravis (practice parameter update): Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.” Neurology (2020). PMID: 32213645 ↗
L1cGUIDELINECited in: Guidelines and Resources - [84]
Skeie GO, Apostolski S, Evoli A et al.. “Guidelines for treatment of autoimmune neuromuscular transmission disorders.” European journal of neurology (2010). PMID: 20402760 ↗
L1cGUIDELINECited in: Guidelines and Resources - [85]
Skeie GO, Apostolski S, Evoli A et al.. “Guidelines for the treatment of autoimmune neuromuscular transmission disorders.” European journal of neurology (2006). PMID: 16834699 ↗
L1cGUIDELINECited in: Guidelines and Resources - [86]
Titulaer MJ, Soffietti R, Dalmau J et al.. “Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.” European journal of neurology (2011). PMID: 20880069 ↗
L1cGUIDELINECited in: Guidelines and Resources - [87]
Elovaara I, Apostolski S, van Doorn P et al.. “EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.” European journal of neurology (2008). PMID: 18796075 ↗
L1cGUIDELINECited in: Guidelines and Resources - [88]
Feasby T, Banwell B, Benstead T et al.. “Guidelines on the use of intravenous immune globulin for neurologic conditions.” Transfusion medicine reviews (2007). PMID: 17397768 ↗
L1cGUIDELINECited in: Guidelines and Resources - [89]
Kimber C, Malouf R, Javan J et al.. “Clinical and economic outcomes of therapeutic plasma exchange and intravenous immunoglobulin for treating adults with autoimmune neurological disorders: a systematic review and meta-analysis.” BMC neurology (2026). PMID: 41794683 ↗
L1aCited in: Supportive Care and Complication Management - [90]
Ma T, Liu Y, Zhu Y et al.. “Effectiveness and Safety of Eculizumab in Highly Active AChR+gMG and Its Therapeutic Response in Different Subtypes of gMG.” ImmunoTargets and therapy (2026). PMID: 41847264 ↗
L4Cited in: Supportive Care and Complication Management - [91]
Rusu D, Lindgren AR, Athari M et al.. “Postoperative Complications Following Spine Surgery in Myasthenia Gravis Patients: A Propensity-Matched National Database Analysis.” Global spine journal (2026). PMID: 42508003 ↗
L3bCited in: Supportive Care and Complication Management - [92]
Wang L, Qu M, Rong X et al.. “Clinical outcomes and quality of life associated with eculizumab in patients with late-onset myasthenia gravis.” Frontiers in immunology (2026). PMID: 42367791 ↗
L4Cited in: Supportive Care and Complication Management - [93]
Chen J, Chen H, Chu X et al.. “Extended Preoperative Immunotherapy Duration Reduces the Risk of Myasthenia Gravis Exacerbation for Patients with Thymoma: A Multicenter Retrospective Cohort Study.” Neurology and therapy (2026). PMID: 42365147 ↗
L3bCited in: Supportive Care and Complication Management - [94]
Zhou Q, He T, Cheng Y et al.. “Efgartigimod Versus Lymphoplasmapheresis as Preoperative Rapid Antibody-Clearing Therapies for Thymectomy in Generalized Myasthenia Gravis: Effectiveness, Safety and Cost Outcomes Compared to Conventional Preparation.” CNS neuroscience & therapeutics (2026). PMID: 42322065 ↗
L3bCited in: Supportive Care and Complication Management - [95]
Suzuki S, Iida M, Wakahara T et al.. “Long-term effectiveness, safety, and cost-effectiveness of intravenous immunoglobulin for generalized myasthenia gravis in an era of molecular targeted drugs: Insights from Japanese post-marketing surveillance.” Journal of autoimmunity (2026). PMID: 42275909 ↗
L3bCited in: Supportive Care and Complication Management - [96]
Chung HY, Yu MH, Shin HY et al.. “Long-Term Mortality in Patients with Myasthenia Gravis: A Nationwide Population-Based Cohort Study in Korea.” Neuroepidemiology (2026). PMID: 42154663 ↗
L3bCited in: Supportive Care and Complication Management - [97]
Dion M, Gavoille A, Chamouard V et al.. “Predictive Factors for Non-response to First Use of Polyvalent Intravenous Immunoglobulin in Generalised Myasthenia Gravis.” Neurology and therapy (2026). PMID: 42091851 ↗
L3bCited in: Supportive Care and Complication Management - [98]
Wang K, Xin H, Zhang M et al.. “Double-Filtration Plasmapheresis Versus Efgartigimod for Generalized Myasthenia Gravis: Severity-Stratified Benefits in a Prospective Observational Multicenter Study.” CNS neuroscience & therapeutics (2026). PMID: 41837820 ↗
L3bCited in: Supportive Care and Complication Management - [99]
McLaren NP, Rosati M, Zhong W et al.. “Comparison of the Efficacy and Safety of Myasthenia Gravis Treatments: A Bayesian Network Meta-Analysis.” Neurology (2026). PMID: 42467874 ↗
L1aCited in: Prognosis and Long-term Outcomes - [100]
Vissing J, Pease S, Scippa K et al.. “Health-related quality of life outcomes with nipocalimab versus placebo in generalized myasthenia gravis: an analysis of the Vivacity-MG3 study.” Journal of neurology (2026). PMID: 42360473 ↗
L1bCited in: Prognosis and Long-term Outcomes - [101]
Howard JF, Saccà F, Hoffmann S et al.. “Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT).” Journal of neurology (2026). PMID: 42234197 ↗
L1bCited in: Prognosis and Long-term Outcomes - [102]
Vu T, Beydoun SR, Nowak RJ et al.. “Evaluation of Sustained Disease Control With Nipocalimab Versus Placebo in the Phase 3 Vivacity-MG3 Study.” European journal of neurology (2026). PMID: 42157574 ↗
L1bCited in: Prognosis and Long-term Outcomes - [103]
Vu T, Habib AA, Jacob S et al.. “Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial.” Lancet (London, England) (2026). PMID: 42030965 ↗
L1bCited in: Prognosis and Long-term Outcomes - [104]
Makus B, Schulze D, Lehnerer S et al.. “Impact of a ketogenic diet on clinical outcomes and immunological markers in myasthenia gravis: A randomized pilot study.” Journal of autoimmunity (2026). PMID: 42000538 ↗
L4Cited in: Prognosis and Long-term Outcomes - [105]
Norling M, Eriksson N, Westerberg E et al.. “Digital Phenotyping and Lifestyle Intervention in Patients With Myasthenia Gravis (DIG-MG): A Randomized Controlled Trial of Feasibility, Adherence, and Effects on Fatigue.” Muscle & nerve (2026). PMID: 41999078 ↗
L4Cited in: Prognosis and Long-term Outcomes - [106]
Budumuri VSK, G AK, Murugadoss H et al.. “Patient-reported health utility in adults with myasthenia gravis: a systematic review and meta-analysis of EQ-5D outcomes.” BMC neurology (2026). PMID: 42231266 ↗
L1aCited in: Prognosis and Long-term Outcomes - [107]
Saccà F, Gialdini G, Howard JF et al.. “Efficacy and Safety of Vemircopan in Generalized Myasthenia Gravis: A Randomized Clinical Trial.” JAMA neurology (2026). PMID: 42043793 ↗
L2bCited in: Prognosis and Long-term Outcomes - [108]
Li YX, Hao YL. “Successful rescue therapy with eculizumab for probable tislelizumab-related MMM overlap syndrome with dual positivity for anti-acetylcholine receptor and anti-titin antibodies: a case report and literature review.” Frontiers in immunology (2026). PMID: 42358974 ↗
L2aCited in: Prognosis and Long-term Outcomes - [109]
Wong HJ, Lee ARYB, Yap QV et al.. “Chimeric antigen receptor-based cellular therapy in autoimmune diseases: A systematic review and meta-analysis of clinical, serological and safety outcomes.” Autoimmunity reviews (2026). PMID: 42167622 ↗
L2aCited in: Prognosis and Long-term Outcomes - [110]
Fernández FJ, Alfonso-González L, Praga M et al.. “Data-augmented machine learning refines the effective-concentration estimate for eculizumab in complement-mediated diseases.” Frontiers in immunology (2026). PMID: 42568413 ↗
L2bCited in: Prognosis and Long-term Outcomes - [111]
An X, Zhu L, Huang X et al.. “Real-world efficacy of eculizumab in generalized myasthenia gravis patients with poor early response to efgartigimod: a prospective cohort study.” Frontiers in immunology (2026). PMID: 42266700 ↗
L4Cited in: Prognosis and Long-term Outcomes - [112]
Tchoudnovski D, Yang D, Ntale I et al.. “Depressive symptoms, but not OSA severity, are associated with general fatigue in myasthenia gravis.” Sleep medicine (2026). PMID: 42070450 ↗
L2bCited in: Prognosis and Long-term Outcomes - [113]
Hershkowitz N, Andrzejczyk A, DeStefano V et al.. “Systematic Review of Chimeric Antigen Receptor T-cell Therapy in Autoimmune Diseases.” Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases (2026). PMID: 42235055 ↗
L2aCited in: Prognosis and Long-term Outcomes - [114]
Alsukhni RA, Al-Ansari A, Hill M. “Early use of low dose rituximab in anti acetylcholine receptor generalized myasthenia gravis in South Wales - A retrospective study.” Journal of the neurological sciences (2026). PMID: 42419026 ↗
L4Cited in: Prognosis and Long-term Outcomes - [115]
Hou C, Zhang Y, Cao X et al.. “A predictive model for low-dose rituximab response in anti-acetylcholine receptor antibody-positive myasthenia gravis: establishment and validation.” Frontiers in immunology (2026). PMID: 42317322 ↗
L3bCited in: Prognosis and Long-term Outcomes - [116]
Vissing J, Coteur G, Turkoz I et al.. “Hospital resource utilization in patients with generalized myasthenia gravis treated with nipocalimab: results from the VIVACITY-MG3 study.” Journal of medical economics (2026). PMID: 42474440 ↗
L1bCited in: Special Populations - [117]
Chae J, Lee MW, Oh SY. “Video-Oculographic Saccadic Fatigability Distinguishes Myasthenia Gravis From Unilateral Ocular Motor Cranial Nerve Palsy in Diplopia: A Prospective Diagnostic Study.” European journal of neurology (2026). PMID: 42504749 ↗
L2bCited in: Special Populations - [118]
Lauletta A, Rossini E, Beretta F et al.. “Comparative Study of Sporadic and Immune Checkpoint Inhibitor-Related Forms of Myasthenia Gravis-Myositis Overlap Syndrome.” Neurology (2026). PMID: 42190146 ↗
L4Cited in: Special Populations - [119]
O'Connor L, Gabrysch K, Wikström AK et al.. “Risk of Myasthenia Gravis Exacerbation During Pregnancy and Postpartum: A Nationwide Cohort Study.” Neurology (2026). PMID: 42127347 ↗
L2bCited in: Special Populations - [120]
Kwon S, Kim BS, Han K et al.. “Rate of Autoimmune Diseases in the 10 Years Preceding Myasthenia Gravis Diagnosis: A Nationwide Cohort Study in South Korea.” Neurology (2026). PMID: 42555884 ↗
L3bCited in: Special Populations - [121]
Shelly S, Ani M, Klein C et al.. “Long-Term Cancer and Mortality After Thymectomy.” European journal of neurology (2026). PMID: 42538851 ↗
L3bCited in: Special Populations - [122]
Aili K, Lu M, Zhao N et al.. “Real-world study of efgartigimod in AChR antibody-positive generalized myasthenia gravis: thymus status, multi-domain symptom improvement and steroid-sparing effect.” Frontiers in immunology (2026). PMID: 42254001 ↗
L3bCited in: Special Populations - [123]
Geng Z, Jiang Y, Xie N et al.. “Tacrolimus as Single-Agent Immunotherapy for Adult-Onset Myasthenia Gravis: Remission, Relapse, and Safety.” CNS neuroscience & therapeutics (2026). PMID: 42223343 ↗
L4Cited in: Special Populations - [124]
Vahldieck C, Fels B. “Complement C5 inhibition in generalized myasthenia gravis is associated with improved survival and increased cardiovascular risk.” Frontiers in immunology (2026). PMID: 42220523 ↗
L4Cited in: Special Populations - [125]
Singh M, Subramanian A, Wambua S et al.. “Autoimmune diseases and risk of adverse pregnancy outcomes: a population-based cohort study of five million pregnancies in the UK.” BMC medicine (2026). PMID: 42169116 ↗
L3bCited in: Special Populations - [126]
Solé G, Salort-Campana E, Pereon Y et al.. “Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.” Revue neurologique (2020). PMID: 32354651 ↗
L1cCited in: Guidelines and Resources - [127]
Cruz S, Matos A, Braz L et al.. “Portuguese Consensus Guidelines for the Diagnosis and Treatment of Myasthenia Gravis.” Acta medica portuguesa (2025). PMID: 41396134 ↗
L1cCited in: Guidelines and Resources - [128]
Bascić-Kes V, Kes P, Zavoreo I et al.. “Guidelines for the use of intravenous immunoglobulin in the treatment of neurologic diseases.” Acta clinica Croatica (2012). PMID: 23540178 ↗
L1cCited in: Guidelines and Resources - [129]
Sanders DB, Lutz MW, Raja SM et al.. “The Duke Myasthenia Gravis Clinic Registry: II. Analysis of outcomes.” Muscle & nerve (2023). PMID: 36734303 ↗
L3bCited in: Guidelines and Resources - [130]
Li Y, Yang S, Dong X et al.. “Diagnostic value of antibody concentration ratio for treatment-refractory myasthenia gravis.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2024). PMID: 38780854 ↗
L3bCited in: Guidelines and Resources - [131]
Yeh HL, Chang CC, Liu AB et al.. “Taiwan Clinical Practice Guidelines for Myasthenia Gravis.” Acta neurologica Taiwanica (2026). PMID: 42033803 ↗
L1cCited in: Guidelines and Resources - [132]
Sussman J, Farrugia ME, Maddison P et al.. “The Association of British Neurologists' myasthenia gravis guidelines.” Annals of the New York Academy of Sciences (2017). PMID: 29121404 ↗
L1cCited in: Guidelines and Resources - [133]
Murai H. “[Transition of Japanese clinical guidelines for myasthenia gravis].” Rinsho shinkeigaku = Clinical neurology (2023). PMID: 37197966 ↗
L1cCited in: Guidelines and Resources - [134]
Watanabe G, Takai Y, Nagane Y et al.. “Cutoffs on severity metrics for minimal manifestations or better status in patients with generalized myasthenia gravis.” Frontiers in immunology (2024). PMID: 39763650 ↗
L3bCited in: Guidelines and Resources - [135]
Ozdemir HN, Karasoy H, Yuceyar AN et al.. “Effects of comorbid diseases on clinical outcomes in patients with myasthenia gravis.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2023). PMID: 36943588 ↗
L3bCited in: Guidelines and Resources - [136]
Narayanaswami P, Sanders DB, Wolfe G et al.. “International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update.” Neurology (2020). PMID: 33144515 ↗
L5Cited in: Guidelines and Resources - [137]
Nowak RJ, Utsugisawa K, Benatar M et al.. “Management of Exacerbations and Rescue Therapy: A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial.” JAMA neurology (2026). PMID: 42573995 ↗
L1bCited in: Clinical Features and Variants - [138]
Gwathmey KG, Saccà F, Howard JF et al.. “Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial.” JAMA neurology (2026). PMID: 42507440 ↗
L1bCited in: Clinical Features and Variants - [139]
Gwathmey KG, Jing P, Laorr S et al.. “Usability and Acceptance of Autoinjector and Prefilled Syringe Devices by Patients with Generalized Myasthenia Gravis in a Human Factors Study.” Advances in therapy (2026). PMID: 42380700 ↗
L1bCited in: Clinical Features and Variants - [140]
Yu F, Myshkin E, Nguyen B et al.. “Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trials.” Human vaccines & immunotherapeutics (2026). PMID: 42084498 ↗
L1bCited in: Clinical Features and Variants - [141]
Verza MU, Schiavolin M, Beretta F et al.. “Clinical Characteristics and Treatment Management of Seronegative Myasthenia Gravis: A Systematic Review of the Literature.” Muscle & nerve (2026). PMID: 42387811 ↗
L2aCited in: Clinical Features and Variants - [142]
Smith AG, Habib AA, Qi CZ et al.. “Clinical efficacy and cost per improved outcome of treatments for generalized myasthenia gravis: evidence from a network meta-analysis and cost-per-responder analysis.” Current medical research and opinion (2026). PMID: 42495790 ↗
L2aCited in: Clinical Features and Variants - [143]
Ma C, Kang N, Zhu Y et al.. “Development and Validation of a Nomogram to Predict Minimal Symptom Expression in AChR+ gMG Patients Undergoing Efgartigimod Therapy.” Current neuropharmacology (2026). PMID: 42634333 ↗
L3bCited in: Clinical Features and Variants - [144]
Abi Aoun M, Beauvais D, Barnay M et al.. “Non-Cyclic Rozanolixizumab Administration in Complex Generalized Myasthenia Gravis.” Muscle & nerve (2026). PMID: 42162585 ↗
L4Cited in: Clinical Features and Variants - [145]
Fang S, Chen YC, Chen S. “Thromboembolic risk in subcutaneous versus intravenous immunoglobulin therapy: a systematic review and narrative meta-synthesis.” Clinical and experimental medicine (2026). PMID: 42268448 ↗
L2aCited in: Supportive Care and Complication Management - [146]
Barnett-Tapia C, Quansah K, Erman A et al.. “Myasthenia Gravis (MG) Resource Utilization, Epidemiology, Survival, and Treatment Patterns (MG-REST): Estimating the Clinical and Economic Burden in Ontario, Canada.” European journal of neurology (2026). PMID: 42629595 ↗
L3bCited in: Supportive Care and Complication Management - [147]
Wei M, Hu T, Yang L et al.. “Immune checkpoint inhibitor-related myositis, myocarditis, and myasthenia gravis overlap syndrome: a systematic review and pooled analysis of individual cases.” Frontiers in immunology (2026). PMID: 42591394 ↗
L4Cited in: Special Populations - [148]
Yang H, Pi X, Cao W et al.. “Hemodynamic response after preoperative embolization in thymoma-associated myasthenia gravis: associations with necrosis, HIF-1α expression, and CD163-positive macrophages.” Frontiers in immunology (2026). PMID: 42682685 ↗
L2bCited in: Special Populations - [149]
Guo R, Zhang Y, Gao T et al.. “Infections and hypogammaglobulinemia in myasthenia gravis patients receiving low-dose rituximab: a real-world cohort study.” Frontiers in immunology (2026). PMID: 42729211 ↗
L3bCited in: Special Populations - [150]
Giannoccaro MP, Serra L, Grondona AG et al.. “Accuracy of Antibody Testing in Myasthenia Gravis: The ADAM Study.” Neurology (2026). PMID: 42579824 ↗
L3bCited in: Special Populations - [151]
Pogosean A, Liik M, van Alfen N et al.. “Exploring the Value of Quantitative Muscle Ultrasound in Neuromuscular Junction Disorders: A Pilot Study.” Muscle & nerve (2026). PMID: 42532974 ↗
L4Cited in: Special Populations - [152]
Vahldieck C, Radermacher PB, Steinmeier P et al.. “Terminal complement inhibition is associated with renal, hematologic, and thrombotic complications during septic shock: A global propensity score-matched cohort study.” Journal of critical care (2026). PMID: 42526359 ↗
L3bCited in: Special Populations - [153]
Grecu N, Mihalache OA, Davidescu EI et al.. “Efgartigimod-alfa therapy in acetylcholine receptor antibody myasthenia gravis: Romanian experience.” Frontiers in neurology (2026). PMID: 42756311 ↗
L1bCited in: Clinical Features and Variants - [154]
Tang P, Xiao K, He Y et al.. “Efficacy of efgartigimod in the treatment of autoimmune encephalitis: a systematic review.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 42726141 ↗
L4Cited in: Clinical Features and Variants - [155]
Betts A, Jacob S, Chakravarty A et al.. “Comparative Efficacy of Zilucoplan Versus Intravenous Immunoglobulin, Eculizumab, and Ravulizumab Using Matching-Adjusted Indirect Comparisons.” Neurology and therapy (2026). PMID: 42786374 ↗
L2bCited in: Clinical Features and Variants - [156]
Maheshwari V, Barnett Tapia C, Chakravarty A et al.. “Comparative Efficacy of Rozanolixizumab with Efgartigimod or Intravenous Immunoglobulin in Generalized Myasthenia Gravis Using Matching Adjusted Indirect Comparisons.” Neurology and therapy (2026). PMID: 42786373 ↗
L2bCited in: Clinical Features and Variants - [157]
Sun C, Liu D, Tang Y et al.. “Effectiveness and safety of telitacicept in refractory ocular myasthenia gravis: a retrospective, real-world study.” Frontiers in immunology (2026). PMID: 42756105 ↗
L4Cited in: Clinical Features and Variants - [158]
Paprad T, Nigro E, Aleisa Z et al.. “Clinical Outcomes and Treatment Efficacy in Juvenile Myasthenia Gravis: A Retrospective Review From a Single Center.” Muscle & nerve (2026). PMID: 42749614 ↗
L4Cited in: Clinical Features and Variants